Oculis Holding AGNASDAQ:OCS
- LAST PRICE14.7900
- TODAY'S CHANGE (%)0.0300 (0.2033%)
- Bid / Lots5.8900/ 2
- Ask / Lots15.7000/ 1
- Open / Previous Close14.8200 / 14.7600
- Day Range
- 52 Week Range
- Volume40,632
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | OCS |
|---|---|---|
| 09:33 ET | 200 | 14.82 |
| 09:35 ET | 268 | 14.89 |
| 09:37 ET | 503 | 14.82 |
| 09:42 ET | 401 | 14.81 |
| 09:48 ET | 800 | 14.82 |
| 09:55 ET | 1400 | 14.81 |
| 10:02 ET | 600 | 14.7 |
| 10:11 ET | 700 | 14.72 |
| 10:26 ET | 600 | 14.72 |
| 10:36 ET | 300 | 14.72 |
| 10:42 ET | 1089 | 14.72 |
| 10:54 ET | 1332 | 14.71 |
| 10:58 ET | 100 | 14.71 |
| 11:00 ET | 100 | 14.71 |
| 11:02 ET | 900 | 14.685 |
| 11:03 ET | 1504 | 14.71 |
| 11:30 ET | 8240 | 14.6107 |
| 11:43 ET | 135 | 14.6695 |
| 11:45 ET | 900 | 14.61 |
| 12:01 ET | 500 | 14.61 |
| 12:15 ET | 500 | 14.61 |
| 12:26 ET | 1100 | 14.61 |
| 12:37 ET | 1362 | 14.605 |
| 12:39 ET | 500 | 14.605 |
| 01:13 ET | 400 | 14.61 |
| 01:36 ET | 400 | 14.61 |
| 01:44 ET | 400 | 14.675 |
| 02:36 ET | 200 | 14.81 |
| 02:38 ET | 200 | 14.81 |
| 02:45 ET | 1100 | 14.79 |
| 02:56 ET | 500 | 14.87 |
| 03:24 ET | 200 | 14.83 |
| 03:28 ET | 862 | 14.79 |
| 03:30 ET | 371 | 14.79 |
| 03:32 ET | 200 | 14.8 |
| 03:37 ET | 478 | 14.79 |
| 03:44 ET | 200 | 14.75 |
| 03:48 ET | 1049 | 14.75 |
| 03:50 ET | 307 | 14.75 |
| 03:51 ET | 600 | 14.72 |
| 03:53 ET | 900 | 14.77 |
| 03:55 ET | 100 | 14.75 |
| 03:57 ET | 865 | 14.75 |
| 04:00 ET | 1841 | 14.79 |
Nov 13, 2024
Oculis to Present at the Stifel 2024 Healthcare Conference, from 4:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
4:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 11, 2024
DJ Oculis Holding Price Target Maintained With a $30.00/Share by HC Wainwright & Co., from 7:11AM ET on Monday Nov 11, 2024 by Dow Jones
7:11AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 7, 2024
Press Release: Oculis Reports Q3 2024 Financial Results and Provides Company Updates, from 4:00AM ET on Thursday Nov 07, 2024 by Dow Jones
4:00AM ET on Thursday Nov 07, 2024 by Dow JonesOculis Reports Q3 2024 Financial Results and Provides Company Updates, from 4:00AM ET on Thursday Nov 07, 2024 by Dow Jones
4:00AM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Oculis Holding AG | 616.2M | -7.4x | --- |
BIOAGE Labs Inc | 686.1M | 0.0x | --- |
Tectonic Therapeutic Inc | 708.7M | -3.5x | --- |
Oric Pharmaceuticals Inc | 676.5M | -5.5x | --- |
Oruka Therapeutics Inc | 726.2M | -3.1x | --- |
Cullinan Therapeutics Inc | 730.2M | -4.4x | --- |
Company Information
Oculis Holding AG is a Switzerland-based company primally engaged in biotechnology sector. The Company is focused on the development of eye disease treatment for ophthalmology. It includes OCS-01, based on the OPTIREACH technology, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED) in a form of a single chain antibody fragment; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and for other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company have operations in the USA, Europe and China. Ocullis deliver treatments to patients worldwide.
Contact Information
- Headquarters
- Bahnhofstrasse 7ZUG, ZUG, Switzerland 6300
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Anthony Rosenberg
- Chief Executive Officer, Director
- Riad Sherif
- Chief Financial Officer
- Sylvia Cheung
- Head - Medical Affairs
- Joanne Chang
- Head - Development
- Bastian Dehmel
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $616.2M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 41.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.05 |
EPS | $-1.99 |
Book Value | $2.86 |
P/E Ratio | -7.4x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
